What is SciReg?
SciReg, Inc. operates as a high-authority consultancy providing essential scientific, regulatory, and quality assurance services. The firm serves a diverse clientele spanning the pharmaceutical, animal health, and chemical industries, acting as a bridge between innovative product research and the stringent requirements of agencies such as the EPA and FDA. Through its deep technical expertise, SciReg facilitates the complex process of obtaining and maintaining product approvals, ensuring that clients can bring their solutions to market efficiently. The recent integration into the Staphyt Group marks a pivotal evolution in the company's trajectory, significantly expanding its global footprint and enhancing its service delivery capabilities in the international regulatory arena.
How much funding has SciReg raised?
SciReg has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in SciReg
PPP
Public-Private Partnership
What's next for SciReg?
With the infusion of this capital, SciReg is well-positioned to accelerate its strategic growth initiatives and deepen its technical service offerings. The focus will likely shift toward scaling its regulatory intelligence platforms and expanding its expert team to meet the increasing demand for compliance-driven market access. As part of the Staphyt Group, SciReg is expected to leverage cross-border synergies to provide more comprehensive support for multinational clients. The firm's roadmap emphasizes maintaining its reputation for excellence while navigating the evolving regulatory frameworks that govern the chemical and life sciences sectors, ensuring long-term stability and continued value creation for its stakeholders.
See full SciReg company page
